SCHEMBL7428204

SCHEMBL7428204

N=C(NCCCN(Cc1ccc(Br)cc1)c1ccccn1)NCCCn1ccnc1

nearest known ligand 0.83

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
SSTR4 P31391 9/20 0.83
SSTR2 P30874 7/20 0.83
HMOX1 P09601 1/20 0.43
ALDH1A1 P00352 1/20 0.43
LMNA P02545 1/20 0.43
GAA P10253 1/20 0.43
NAMPT P43490 3/20 0.42
HDAC1 Q13547 3/20 0.42
QPCT Q16769 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
HDAC3 O15379 1/20 0.42
NCOR1 O75376 1/20 0.42
HDAC4 P56524 1/20 0.42
HDAC2 Q92769 1/20 0.42
HDAC8 Q9BY41 1/20 0.42
HDAC6 Q9UBN7 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7421851 0.91 SSTR4 (1.00) SSTR4SSTR2QPCT
Bromide SCHEMBL7424764 0.90 SSTR4 (0.98) SSTR4SSTR2QPCT
SCHEMBL7421605 0.88 SSTR4 (1.00) SSTR4SSTR2GAAQPCT
SCHEMBL7430124 0.81 SSTR4 (0.56) SSTR4SSTR2ALDH1A1LMNA
SCHEMBL7421882 0.81 SSTR4 (0.61) SSTR4SSTR2
SCHEMBL7425212 0.80 SSTR4 (0.82) SSTR4SSTR2ALDH1A1LMNASMN1; SMN2
SCHEMBL7429330 0.78 SSTR4 (0.56) SSTR4SSTR2ALDH1A1
SCHEMBL7427056 0.76 SSTR4 (1.00) SSTR4SSTR2ALDH1A1QPCT
SCHEMBL7476252 0.75 SSTR4 (0.61) SSTR4SSTR2ALDH1A1
SCHEMBL7421416 0.75 SSTR4 (0.51) SSTR4SSTR2LMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1019050-B1 USE OF SOMATOSTATIN AGONISTS AND ANTAGONISTS FOR TREATING DISEASES RELATED TO THE EYE NOVO NORDISK AS (DK) 2002-03-20 EP claimed
US-6159941-A Use of somatostatin agonists and antagonists for treating diseases related to the eye NOVO NORDISK A/S (DK) 2000-12-12 US claimed
US-6127343-A SELECTIVE, COMPETITIVE SOMATOSTATIN RECEPTOR LIGANDS OF NONPEPTIDE ORIGIN, FOR MEDIATING THE BIOLOGICAL EFFECT OF SOMATOSTATIN AGONISTS OR ANTAGONIST NOVO NORDISK A/S (DK) 2000-10-03 US claimed
EP-1019050-A1 USE OF SOMATOSTATIN AGONISTS AND ANTAGONISTS FOR TREATING DISEASES RELATED TO THE EYE NOVO NORDISK A/S (DK) 2000-07-19 EP claimed
EP-0912551-A1 SOMATOSTATIN AGONISTS AND ANTAGONISTS NOVO NORDISK A/S (DK) 1999-05-06 EP claimed
WO-1998058646-A1 USE OF SOMATOSTATIN AGONISTS AND ANTAGONISTS FOR TREATING DISEASES RELATED TO THE EYE NOVO NORDISK A/S (DK) 1998-12-30 WO claimed
WO-1997043278-A1 SOMATOSTATIN AGONISTS AND ANTAGONISTS NOVO NORDISK A/S (DK) 1997-11-20 WO claimed
EP-1019050-B1 USE OF SOMATOSTATIN AGONISTS AND ANTAGONISTS FOR TREATING DISEASES RELATED TO THE EYE NOVO NORDISK AS (DK) 2002-03-20 EP disclosed
US-6159941-A Use of somatostatin agonists and antagonists for treating diseases related to the eye NOVO NORDISK A/S (DK) 2000-12-12 US disclosed
US-6127343-A SELECTIVE, COMPETITIVE SOMATOSTATIN RECEPTOR LIGANDS OF NONPEPTIDE ORIGIN, FOR MEDIATING THE BIOLOGICAL EFFECT OF SOMATOSTATIN AGONISTS OR ANTAGONIST NOVO NORDISK A/S (DK) 2000-10-03 US disclosed
EP-1019050-A1 USE OF SOMATOSTATIN AGONISTS AND ANTAGONISTS FOR TREATING DISEASES RELATED TO THE EYE NOVO NORDISK A/S (DK) 2000-07-19 EP disclosed
EP-0912551-A1 SOMATOSTATIN AGONISTS AND ANTAGONISTS NOVO NORDISK A/S (DK) 1999-05-06 EP disclosed
WO-1998058646-A1 USE OF SOMATOSTATIN AGONISTS AND ANTAGONISTS FOR TREATING DISEASES RELATED TO THE EYE NOVO NORDISK A/S (DK) 1998-12-30 WO disclosed
WO-1997043278-A1 SOMATOSTATIN AGONISTS AND ANTAGONISTS NOVO NORDISK A/S (DK) 1997-11-20 WO disclosed